Trial Profile
A Phase 1, Randomized, Placebo-and Positive-Controlled Crossover Study to Determine the Effect of Single-Dose GC4419 on QTc Interval in Healthy Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 19 Dec 2018
Price :
$35
*
At a glance
- Drugs Avasopasem manganese (Primary) ; Moxifloxacin
- Indications Head and neck cancer; Pancreatic cancer; Stomatitis
- Focus Adverse reactions
- Sponsors Galera Therapeutics
- 15 Nov 2017 Status changed from not yet recruiting to completed.
- 25 May 2017 New trial record